These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 10794108

  • 1. Cost-effectiveness of new blood safety technologies.
    AuBuchon JP.
    Dev Biol (Basel); 2000; 102():211-5. PubMed ID: 10794108
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Down the road to product analysis, step by step. Medical Alley's Cost-Effectiveness Task Force.
    Mater Manag Health Care; 1995 Sep; 4(9):24. PubMed ID: 10151136
    [No Abstract] [Full Text] [Related]

  • 10. [The precautionary principle: advantages and risks].
    Tubiana M.
    J Chir (Paris); 2001 Apr; 138(2):68-80. PubMed ID: 11319454
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk assessment and cost-effectiveness/utility analysis.
    Busch M, Walderhaug M, Custer B, Allain JP, Reddy R, McDonough B.
    Biologicals; 2009 Apr; 37(2):78-87. PubMed ID: 19243972
    [Abstract] [Full Text] [Related]

  • 13. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses.
    Wisher M.
    Cancer Gene Ther; 2002 Dec; 9(12):1056-61. PubMed ID: 12522444
    [Abstract] [Full Text] [Related]

  • 14. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ.
    Dev Biol Stand; 1993 Dec; 81():221-9. PubMed ID: 8174806
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Conclusions. The precautionary principle: its advantages and risks].
    Tubiana M.
    Bull Acad Natl Med; 2000 Dec; 184(5):969-93. PubMed ID: 11077719
    [Abstract] [Full Text] [Related]

  • 20. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer.
    Lee DC, Miller JL, Petteway SR.
    Haemophilia; 2002 Mar; 8 Suppl 2():6-9. PubMed ID: 11966845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.